Do you want to read an article? Please log in or register.
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Migraine and Headache
RECOMMENDED
Related content
Migraine and Headache
Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies
Headache.
Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C
doi: 10.1111/head.13636.
RECOMMENDED
Migraine and Headache
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
Cephalalgia.
Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D
doi: 10.1177/0333102419864132.
RECOMMENDED
Migraine and Headache
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache.
Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, Yu SY, Finnegan M, Severt L, Trugman JM
doi: 10.1111/head.13682.
RECOMMENDED
Migraine and Headache
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 3
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache.
Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN
doi: 10.1111/head.13766.
RECOMMENDED
Migraine and Headache
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Lancet.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB
doi: 10.1016/S0140-
RECOMMENDED
Migraine and Headache
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
JAMA.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM
doi: 10.1001/jama.2019.16711.
Migraine and Headache
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
BMC Neurol.
Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL
doi: 10.1186/s12883-018-1193-2.
Migraine and Headache
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Headache
Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD
doi: 10.1111/head.14138
Migraine and Headache
STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
Headache
Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB
doi: 10.1111/head.14184